# IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

> **NCT05827796** · PHASE1,PHASE2 · RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** IN10018
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** KN046

## Key facts

- **NCT ID:** NCT05827796
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-08
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827796, "IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05827796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*